These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
182 results:

  • 1. Association of Schimmelpenning Syndrome with Astrocytoma (WHO Grade 3): Case Report.
    Tumova A; Auslands K; Millers A; Priede Z; Buks M; Ozola A; Ozoliņa E; Bicāns K; Ulmanis R
    Medicina (Kaunas); 2024 Oct; 60(10):. PubMed ID: 39459475
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Survival outcomes and molecular drivers of testicular cancer in hispanic men.
    Rezaee ME; Elias R; Li HL; Agrawal P; Pallauf M; Enikeev D; Ged Y; Eggener S; Singla N
    Urol Oncol; 2024 Sep; 42(9):293.e1-293.e7. PubMed ID: 38821727
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Neurofibromatosis type 1 associated with pheochromocytoma: a case report with a brief review of the literature].
    Lugovskaya AY; Britvin TA; Gurevich LE; Rog IS; Nefedova LN; Ilovayskaya IA
    Probl Endokrinol (Mosk); 2023 Sep; 70(2):53-64. PubMed ID: 38796761
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
    Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
    Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
    [No Abstract]    [Full Text] [Related]  

  • 5. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
    Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
    Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.
    Darabi S; Adeyelu T; Elliott A; Sukari A; Hodges K; Abdulla F; Zuazo CE; Wise-Draper T; Wang T; Demeure MJ
    J Am Coll Surg; 2024 Jul; 239(1):50-60. PubMed ID: 38651727
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing kras stability.
    Zhao F; Yao Z; Li Y; Zhao W; Sun Y; Yang X; Zhao Z; Huang B; Wang J; Li X; Chen A
    Cancer Lett; 2024 May; 590():216844. PubMed ID: 38582394
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities.
    Li B; Zhao S; Li S; Li C; Liu W; Li L; Cui B; Liu X; Chen H; Zhang J; Ren Y; Liu F; Yang M; Jiang T; Liu Y; Qiu X
    Neuro Oncol; 2024 Jul; 26(7):1335-1351. PubMed ID: 38430549
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression.
    Bai X; Li S; Luo Y
    Int Ophthalmol; 2024 Feb; 44(1):55. PubMed ID: 38342795
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. kras is a molecular determinant of platinum responsiveness in glioblastoma.
    Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
    BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
    Iorgulescu JB; Ruthen N; Ahn R; Panagioti E; Gokhale PC; Neagu M; Speranza MC; Eschle BK; Soroko KM; Piranlioglu R; Datta M; Krishnan S; Yates KB; Baker GJ; Jain RK; Suvà ML; Neuberg D; White FM; Chiocca EA; Freeman GJ; Sharpe AH; Wu CJ; Reardon DA
    Front Immunol; 2023; 14():1297932. PubMed ID: 38213329
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-cell neuroendocrine carcinoma.
    Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
    Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
    de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
    Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
    Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
    Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
    Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
    Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The Unmet Diagnostic and treatment Needs in Large cell Neuroendocrine Carcinoma of the Lung.
    Buium C; Negru S; Ionescu DN; Dediu M
    Curr Oncol; 2023 Jul; 30(8):7218-7228. PubMed ID: 37623004
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis.
    Zheng K; Hao F; Medrano-Garcia S; Chen C; Guo F; Morán-Blanco L; Rodríguez-Perales S; Torres-Ruiz R; Peligros MI; Vaquero J; Bañares R; Gómez Del Moral M; Regueiro JR; Martínez-Naves E; Mohamed MR; Gallego-Durán R; Maya D; Ampuero J; Romero-Gómez M; Gilbert-Ramos A; Guixé-Muntet S; Fernández-Iglesias A; Gracia-Sancho J; Coll M; Graupera I; Ginès P; Ciudin A; Rivera-Esteban J; Pericàs JM; Frutos MD; Ramos Molina B; Herranz JM; Ávila MA; Nevzorova YA; Fernández-Malavé E; Cubero FJ
    Cell Death Dis; 2023 Aug; 14(8):514. PubMed ID: 37563155
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Prognostic biomarkers for survival in mucosal melanoma.
    Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
    Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study.
    Scherzad A; Stöth M; Meyer TJ; Haug L; Gehrke T; Schilling B; Meierjohann S; Scheich M; Hagen R; Gesierich A; Hackenberg S
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4215-4223. PubMed ID: 37272953
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine tumors and Metastases.
    Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
    Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.